A B S T R A C T To evaluate the contribution of genetic influences on the individual variation in plateau serum salicylate levels, salicylate metabolism was studied in seven pairs of identical and six pairs of fraternal twins.
INTRODUCTION
There are large individual differences in the aspirin dosage required to achieve adequate serum salicylate levels for the treatment of rheumatoid arthritis, rheumatic fever, and similar diseases. This is of special clinical importance because intensive salicylate therapy for these disorders requires the use of doses large enough to maintain salicylate concentrations juist below the toxic range. Indeed, serious intoxication can result from salicylate administration in the therapeutic-dose range, especially in children (1, 2) . On the other hand, an inadequate concentration may be the cause of therapeutic failure.
Published reports demonstrate significant individual differences in salicylate elimination rates as well as serum salicylate levels at constant doses (3) (4) (5) (6) (7) . However, no satisfactory explanation of this individual variability is documented.
Levy and his associates (8) (9) (10) (11) and others (6, 12) have demonstrated that aspirin metabolism is governed by parallel first-order and Michaelis-Menton kinetics. The excretion of two major metabolites of salicylic acid, viz, salicyluric acid and salicyl phenolic glucuronide is capacity limited in the usual therapeuticdosage range. Thus, the excretion rates of salicyluric acid and of salicyl phenolic glucuronide are limited by the body's capacity to produce these metabolites. It is conceivable that individual differences in the maximal capacities of these pathways of salicylate metabolism could be responsible for intersubject variation of salicylate levels. This METHODS Seven pairs of identical twins (four male and three female sets) and seven pairs of fraternal twins (four male-female, two male, and one female set), with ages between 16 and 27 yr, volunteered for this study. Twins were accepted sequentially into the study as they volunteered (given that they were normal, see below, and of acceptable age). Informed consent was obtained from all individuals and from their parents where appropriate. Typing of the identical twin volunteers for 26 erythrocyte groups determined that they were identical. In the cases of the fraternal twins, sex and phenotypic differences demonstrated nonidentity; if fraternal twins appeared physically similar, they were also typed for 26 erythrocyte groups to document nonidentity.
Copies of the birth certificates were obtained from the fraternal twins as proof of sibship. All were normal healthy individuals as determined by history, complete physical examination, and routine laboratory tests (including serum creatinine, alkaline phosphatase, serum glutamic oxaloacetic-acid-transaminase, serum glutamic pyruvic transaminase, total protein, albumin, and urinalysis) and had normal kidney and liver function. None-had received any medication for at least 6 wk before the study except [9] [10] [11] [12] g/day, was given in divided doses every 4 h, skipping the night dose, to maintain the urine pH in the range of 5.0 or below. Acidification of urine minimizes the pH-dependent excretion of free salicylic acid (13), a variable which we desired to minimize for this study of individual metabolic differences. The subjects received ammonium chloride for 48 h before hospitalization and for 24 h of equilibration in the hospital. After this, a single dose of sodium salicylate, 40 mg/kg, was given i.v., followed by frequent timed collections of blood for 48 h and urine samples for at least 48 and up to 72 h after the injections. Blood was allowed to clot and serum was separated and immediately frozen for subsequent analysis. The total volume of each urine specimen was measured, and the pH was determined immediately after voiding; an aliquot was then frozen.
Serum salicylate was assayed by the single extraction method of Stevenson (14) . According to this method, 0.5 ml of serum is extracted with a solution of malonic acid in 5 ml butyl ether. The ultraviolet absorption peak at 307 nm is used for identification and determination of salicylic acid. The absorbance readings obtained in repeated determinations, when standard solutions containing 10 or 20 mg/dl were treated in the same manner as serum, were within 5% of the mean value.
Free acid glucuronides (SAG), as well as total salicylic acid (TSA) in urine, were estimated by the colorimetric method of Levy and Procknal (15) . The method consists of: (a) determination of FSA by extraction of the sample with carbon tetrachloride and re-extraction into ferric nitrate reagent solution; (b) determination of absorbance due to both FSA and SU by extraction of the sample with ethylene dichloride and re-extraction into ferric nitrate solution; and (c) determination of TSA (i.e. FSA, SU, and SAG) after complete acid hydrolysis of these inetabolites to salicylic acid (SA) followed by step (a). SU content is calculated by the difference between (a) and (b) and SAG content is determined by subtracting FSA and SU values from (c). Absorbance peak was read at 530 nm using a Beckman DU spectrophotometer (Beckman Instruments, Inc., Fullerton, Calif.). Repeated determinations of standard solutions containing 10 mg of salicyclic acid/100 ml and 50 mg of salicyluric acid/100 ml, treated in the same manner as urine, showed a coefficient of variation of 4%. Gentisic acid excretion was not determined.
After the acute study, and after at least 3 wk without medication, the same pairs oftwins were treated as outpatients with 65 mg/kg per day of buffered aspirin (Ascriptin, William H. Rorer, Inc., Fort Washington, Pa.) given orally in five divided doses at 4-h intervals, skipping the night dose, concomitantly with ammonium chloride (6-8 g per day) to acidify the urine (kept at a pH of 5.0). After 3 days of aspirin therapy, the plateau serum salicylate levels and urinary FSA, SU, SAG, and TSA were determined during the second dosing interval on the fourth day as follows: blood and urine samples were collected immediately before and 1, 2, and 3 h after the last dose and the salicylate contents were determined as in the acute studies.
Data treatment. 
where X1, represents one member ofa twin pair, Xi2 represents the other member, and N is the number of pairs (17) . The heritability factor was determined according to the formula:
where VDz is the variance between members of a dizygotic twin pair and VMZ is the variance between members of a monozygotic twin pair (18 (Table III) was 0.92+0.02 mg/kg per h for the identical twins and 0.91+0.03 mg/kg per h for the fraternal twins (P > 0.5, Student's t test). Extimations of the Michaelis-Menton constant, Vm, were calculated from Eq. 1. Plots of the best and worst fit to this equation are shown in Fig. 2 . The mean Vm for SU was 66.3±4.1 mg/h for the identical twins and 64.7+5.5 mg/h for the fraternal twins (P > 0.5).
The SE of the estimates for the individual Vm's, as well as correlation coefficients, may be found in Table III . The time required to excrete 50% of the total injected dose of 40 mg/kg, determined from cumulative excretion curves, was 15.2±0.7 h for the monozygotic twins and 13.9+0.6h for the dizygotic twins (P > 0.5). Ranges are seen in Table II . Table V shows the results of the Mann-Whitney U test, testing intrapair differences among monozygotic twins as compared to intrapair differences among dizygotic twins. It also shows heritability (calculated according to equations 2 and 3) for SU and total salicylate excretion and appropriate intraclass correlation coefficients (Eq. 4). After the i.v. dose, the intrapair differences for monozygotic twins were not significantly smaller than for the dizygotic twins with respect to the maximum observed sustained SU excretion rate (P = 0.53). The P value for the Vm of SU was greater than 0.5, and the P value for the estimation of the hours to 50% excretion of the total salicylate dose was 0.29.
Oral multiple-dose treatment. Table IV shows serum salicylate levels and the urinary excretion rate of SU and of TSA after the twins were treated with 72 h of oral aspirin therapy (65 mg/kg per day).
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Although we realize that these subjects were not yet at steady state, they were approaching plateau and, as can be seen from the data in Table IV , serum levels were relatively constant over the period of outpatient sampling (27.7+1.0 mg/dl for the identical twins; 22.9 ±+1.8 mg/dl for the fraternal twins). The mean serum salicylate levels, SU excretion rates, and TSA excretion after multiple doses of aspirin were not statistically different when comparing the identical and fraternal twins (P > 0.1, 0.5, and 0.5, respectively) (Table IV) . The intrapair differences between the multiple-dose serum salicylate levels for the identical twins were significantly smaller than for the dizygotic twins (P = 0.04). For SU excretion, the identical vs. nonidentical twin differences had a probability of 0.067. The intrapair differences between the identical twins were significantly smaller than those between the fraternal twins for TSA excretion (P = 0.006). The heritability and intraclass correlation coefficients for all of the above substances are listed in Table V. It is of interest that the SU excretion rate in milligrams/kilogram per hour in the oral multiple-dose treatment increased by a mean of 50.5+5.1% (range: 9-96%) when compared to the single i.v. dose SU excretion rate in milligrams/kilogram per hour (Tables  III and IV) .
Although there were seven pairs of identical and seven pairs of fraternal twins entered in the study, one pair of fraternal twins was given an incorrect dose of salicylate i.v. A different set of fraternal twins apparently misunderstood the instructions for the multiple-dose study, and took only 300 mg/day, thus invalidating their results for this portion of the study. Therefore, only six sets offraternal twins were analyzed in each portion of the study.
Since there were four male-female sets of dizygotic twins, it was possible that sex differences might have led to some systematic bias in the results. This possibility was tested by looking at all the males versus all the females and ascertaining if any statistically significant differences occurred between these two groups. When all the parameters tested in Table V (Statistical Summary) were compared in this way, there were no significant differences found between males and females except in the Vm. Here there was no normalization of weights, since Vm is in mg/h, and it would not be surprising to find a difference. Even here, when looking at the actual population where bias might occur (the fraternal twins), there was no significant difference found (P = 0.12).
DISCUSSION
This study in identical and fraternal twins suggests that some aspects of salicylate metabolism are genetically determined. Other drugs have set some precedent for this finding. Significant interindividual differences in steady-state plasma levels and biological half-lives of antipyrine (20, 21) , alcohol (22) , phenylbutazone (23), dicumarol (24) , nortriptyline (25) , and isoniazid (26) have been demonstrated and attributed to genetically determined differences in drug metabolism.
A commonly used twin method for determining the contribution of genetic versus environmental factors employs a comparison of mean monozygotic and mean dizygotic variance observed in two groups of twins (18, 27) . This method was used here to compute heritability and intraclass correlation coefficients. Although heritability (H) may appear to quantitate genetic influence, used alone it may be misleading, and it is useful to look at the intraclass correlation coefficient (r) at the same time. According to Neel and Schull, r is a ". . . linear function of the ratio of two variances-the variance between members of a twin- pair and the variance over the whole set of observations . . ." (27) . They suggest that comparison of r,,, to rDZ is the best comparison to appraise the relative contribution of genetic and environmental effects. Thus, the higher the r, the less difference exists between twin pairs, and the lower the r, the more the difference. Similar r's indicate lack of large differences between sets of twins despite apparently large H. As groups, the identical and fraternal twins were not significantly different with respect to age, weight, domicile, TSA, FSA, SU, and SAG excretion, or serum salicylate concentrations, indicating that both groups of twins are members of the same population with respect to these factors.
Serum salicylate concentration was plotted versus time. From Fig. 1 , one can see that a linear relationship seems to exist, although Levy (10) showed that the decline ofserum sodium salicylate over the range of this study (approximately 30-5 mg/dl) is described by parallel first-order and Michaelis-Menton kinetics, which results in a curvilinear plot. FSA, salicyl acyl glucuronide, and gentisic acid excretion follow firstorder kinetics, whereas, salicylurate and salicyl phenol glucuronide excretion follow Michaelis-Menton kinetics (10) . In the present study, FSA was kept to a Salicylate Metabolism in Twins 37 we did not include the K.'s in our analysis.
Upon measuring the SU excretion rate after 3 days of oral therapy, we found smaller differences between identical than fraternal twins with a P = 0.067 (Table  V) . H appeared to be significant (0.89) whereas the r's were only 0.18 apart (rmz = 0.94; rDz = 0.76). Thus, there were indications of genetic influence during the 3-day oral study but not during acute i.v. dose study. Part of the explanation for this apparent inconsistency may lie in another surprising finding; the maximum observed sustained SU excretion rates after 3 days of aspirin therapy were 50.5±5.1% greater than those observed during the initial single i.v. dose of sodium salicylate. Even though SU excretion is capacity limited, one could object that the dose of salicylate given was larger during the outpatient portion of the study, so one would expect SU excretion to rise. It is, in fact, true that on a mole for mole basis, there was a 44.4% increase in dose during the outpatient study. However, this would only be expected to cause a change in SU excretion from the mean observed maximum SU excretion of 58.0 mg/h to one no higher than 59.7 mg/h (see Appendix A); instead the observed plateau SU excretion rate was 87.0 mg/h (Table  IV) . Since SU excretion is capacity limited, the only reasonable explanation is an increase in the capacity for SU formation, i.e., induction of glycine synthetase, the enzyme responsible for SU formation. Induction of SU production has not been previously demonstrated. It appeared to occur quickly (over a 3-day period) compared to meprobamate and phenylbutazone which takes weeks to months, but induction of enzymes metabolizing polycyclic hydrocarbons has been documented within 3-6h in rats (21, 29, 30) . Further support for this finding comes from Muller et al. who showed falling serum levels of salicylate over time while his subjects were taking a constant dose of aspirin (31) . It should be noted that all subjects were specifically asked about recent ingestion of aspirin or salicylate-containing drugs, and denied After uniform induction with high-dose oral therapy, however, these genetic differences might again have manifested themselves, hence no statistically significant differences, low H, and r's during the i.v. study, but statistically significant differences and higher H during the longer study (Table V) . Besides the previous exposure to salicylates, the metabolism of drugs may be influenced by other environmental factors (32) . For salicylates, the excretion of one of the important metabolites, FSA, is known to be dependent on urinary pH (13) . In the present study, FSA excretion was almost completely prevented by the administration of ammonium chloride to acidify the urine. Other factors which might help explain Salicylate Metabolism in Twins 39 "For P = 0.05, the initial value of F is 6.98, comparing seven pairs of identical twins with six pairs of fraternal twins, using a 2-tailed analysis.
the differences between the acute and plateau SU excretion rates may relate to variations in absorption kinetics, since the acute study involved an i.v. dose and the multiple-dose study involved oral doses. When examining the serum salicylate levels achieved in these young healthy subjects, it was found that the mean serum salicylates ranged from 11.9 to 36.4 mg/dl after 65-mg/kg per day dosing for 3 days. This range is appreciably less than the range previously reported in rheumatoid arthritis patients (7) . The difference between that study and the present one suggests the possibility that disease state and/or age may also play a role in determining individual salicylate levels, in addition to the hereditary factors seen in these young, healthy individuals.
The individual twins ofthree identical pairs and four fraternal pairs lived apart, in different households. Environmental influences were, therefore, similarly randomized for the sets of identical and fraternal twins. Although not rigidly controlled, we feel the equal distribution of environmental differences minimizes bias contributed by this factor.
This study documents a genetic influence on the control of salicylate metabolism and suggests that salicylurate formation is inducible. Fig. 3 .
From Table III Fig. 3 it is seen that this value is on the flat part of the curve (i.e. approaching Vm) where changes in S using a Km = 338 (from ref. 10 This is the predicted SU excretion rate, at steady state, for a 44.4% increase in dose from 2,231 mg. In our study we were not at steady state yet, so our predicted change would be less than this. Nevertheless we used the steady-state predicted value described above to be conservative in our interpretation.
